ArticleFrontiers in microbiology2018
Advancement of the 5-Amino-1-(Carbamoylmethyl)-1H-1,2,3-Triazole-4-Carboxamide Scaffold to Disarm the Bacterial SOS Response.
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Bacterial mutation dynamics emerging insights into virulence evolution and drug resistance. A review study.Frontiers in medicine · 2026Review
- Identification and Characterization of a Small-Molecule Inhibitor of theACS infectious diseases · 2025Article
- Snapshots ofiScience · 2025Article
- Review
- A small molecule that inhibits the evolution of antibiotic resistance.NAR molecular medicine · 2024Article
- Drugging evolution of antibiotic resistance at a regulatory network hub.Science advances · 2023Article
- Integration of molecular modelling andFrontiers in cellular and infection microbiology · 2023Article
- Engineered RecA Constructs Reveal the Minimal SOS Activation Complex.Biochemistry · 2022Article
- Identification of Small Molecule Inhibitors against Mycobacteria in Activated Macrophages.Molecules (Basel, Switzerland) · 2022Article
- Filamentous morphology of bacterial pathogens: regulatory factors and control strategies.Applied microbiology and biotechnology · 2022Review
- Exploration of inhibitors of the bacterial LexA repressor-protease.Bioorganic & medicinal chemistry letters · 2022Article
- RecA and Specialized Error-Prone DNA Polymerases Are Not Required for Mutagenesis and Antibiotic Resistance Induced by Fluoroquinolones inAntibiotics (Basel, Switzerland) · 2022Article
- Prophage Activation in the Intestine: Insights Into Functions and Possible Applications.Frontiers in microbiology · 2021Review
- Targeting evolution of antibiotic resistance by SOS response inhibition.Computational and structural biotechnology journal · 2021Review
- Targeting evolution to inhibit antibiotic resistance.The FEBS journal · 2020Review
- The Kinetic and Molecular Basis for the Interaction of LexA and Activated RecA Revealed by a Fluorescent Amino Acid Probe.ACS chemical biology · 2020Article
- Betulinic Acid Prevents the Acquisition of Ciprofloxacin-Mediated Mutagenesis inMolecules (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Many antibiotics, either directly or indirectly, cause DNA damage thereby activating the bacterial DNA damage (SOS) response. SOS activation results in expression of genes involved in DNA repair and mutagenesis, and the regulation of the SOS response relies on two key proteins, LexA and RecA. Genetic studies have indicated that inactivating the regulatory proteins of this response sensitizes bacteria to antibiotics and slows the appearance of resistance. However, advancement of small molecule inhibitors of the SOS response has lagged, despite their clear promise in addressing the threat of antibiotic resistance. Previously, we had addressed this deficit by performing a high throughput screen of ∼1.8 million compounds that monitored for inhibition of RecA-mediated auto-proteolysis of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.